Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
about
Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variantsPharmacogenomics and cardiovascular diseaseNo evidence for cardiac dysfunction in Kif6 mutant miceGenome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapyA common KIF6 polymorphism increases vulnerability to low-density lipoprotein cholesterol: two meta-analyses and a meta-regression analysisMeta-analyses of KIF6 Trp719Arg in coronary heart disease and statin therapeutic effect.Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testingEffect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart diseaseJUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses.Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promisesCardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group.Pharmacogenetics and cardiovascular disease--implications for personalized medicineThe Association between KIF6 Single Nucleotide Polymorphism rs20455 and Serum Lipids in Filipino-American WomenStatin dose in Asians: is pharmacogenetics relevant?Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.Pharmacogenomics of lipid-lowering therapies.Genetics and personalized medicine--a role in statin therapy?Seventeen years of statin pharmacogenetics: a systematic review.KIF6 719Arg Genetic Variant and Risk for Thoracic Aortic Dissection.Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial.Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.
P2860
Q24273409-9626874F-8AB3-4C6F-BBD4-E52491D916C1Q26997380-BDFAB8A0-916B-4E39-87D2-6D7C1C2B82BEQ28485242-CB63B32F-2437-4131-95B4-FB42AEA58274Q28729086-6430384D-074C-4A24-A757-C365B14CBDC2Q34117006-F8EF0672-876C-4FED-8DB4-082A58E7E65DQ34317404-A8F52D9E-19E7-4784-BBA1-1D855300FECBQ34608646-8C4CFD80-168B-4500-B15B-25F41C3C8024Q34852756-F14A3EB0-0C9F-4446-88F7-74B75CBC1082Q35172886-DFBE25BB-1898-4CF9-B30C-4E07BA148441Q35190833-4075FAE1-608E-44E7-A398-A82819776E9CQ36366330-1BF2ED93-CC6A-4927-8563-C50BDB6E84BFQ36974672-F6C29ACB-8639-4D73-9A1B-C74C6A78CE0FQ37576928-E23B79B0-36F4-4EA7-A67E-47E81ACD5BA9Q37951651-AC5955CB-1A5F-4F57-9EDA-99B805AA46E8Q38094070-352ED891-4EEE-4AFB-8DDC-B84F6DD86DA1Q38097339-3317F379-86F8-4C84-81CC-37D014CD6C51Q38112823-A57C6623-1C9D-4A83-99FD-D4C5C2CB0CC3Q38167710-2F56EC8B-0FEE-4FF5-84B1-90B92896656CQ38670109-321419A2-DF0D-4101-8150-2F7397E18CE6Q40883660-31C9987F-0D4A-474B-87B2-266CCE3DFA6AQ43511456-172AA629-60C4-4B1B-837E-FE1130A03004Q44107102-6F05AB3B-93BC-4E0A-9CCC-943B4A981309
P2860
Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Kinesin-like protein 6 (KIF6) ...... astatin in primary prevention.
@en
type
label
Kinesin-like protein 6 (KIF6) ...... astatin in primary prevention.
@en
prefLabel
Kinesin-like protein 6 (KIF6) ...... astatin in primary prevention.
@en
P2093
P1476
Kinesin-like protein 6 (KIF6) ...... astatin in primary prevention.
@en
P2093
Daniel I Chasman
Jean G MacFadyen
Paul M Ridker
Robert J Glynn
P304
P356
10.1161/CIRCGENETICS.110.959353
P577
2011-04-14T00:00:00Z